These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 24166615)

  • 1. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood.
    Belzil VV; Bauer PO; Prudencio M; Gendron TF; Stetler CT; Yan IK; Pregent L; Daughrity L; Baker MC; Rademakers R; Boylan K; Patel TC; Dickson DW; Petrucelli L
    Acta Neuropathol; 2013 Dec; 126(6):895-905. PubMed ID: 24166615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients.
    Belzil VV; Bauer PO; Gendron TF; Murray ME; Dickson D; Petrucelli L
    Brain Res; 2014 Oct; 1584():15-21. PubMed ID: 24530272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of C9orf72 expansion reduces RNA foci formation and dipeptide-repeat proteins expression in cells.
    Bauer PO
    Neurosci Lett; 2016 Jan; 612():204-209. PubMed ID: 26690922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS.
    Gendron TF; Bieniek KF; Zhang YJ; Jansen-West K; Ash PE; Caulfield T; Daughrity L; Dunmore JH; Castanedes-Casey M; Chew J; Cosio DM; van Blitterswijk M; Lee WC; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
    Acta Neuropathol; 2013 Dec; 126(6):829-44. PubMed ID: 24129584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making sense of the antisense transcripts in C9FTD/ALS.
    Todd PK
    Acta Neuropathol; 2013 Dec; 126(6):785-7. PubMed ID: 24178412
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular Mechanisms of Neurodegeneration Related to
    Babić Leko M; Župunski V; Kirincich J; Smilović D; Hortobágyi T; Hof PR; Šimić G
    Behav Neurol; 2019; 2019():2909168. PubMed ID: 30774737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.
    Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW
    Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study.
    Gijselinck I; Van Langenhove T; van der Zee J; Sleegers K; Philtjens S; Kleinberger G; Janssens J; Bettens K; Van Cauwenberghe C; Pereson S; Engelborghs S; Sieben A; De Jonghe P; Vandenberghe R; Santens P; De Bleecker J; Maes G; Bäumer V; Dillen L; Joris G; Cuijt I; Corsmit E; Elinck E; Van Dongen J; Vermeulen S; Van den Broeck M; Vaerenberg C; Mattheijssens M; Peeters K; Robberecht W; Cras P; Martin JJ; De Deyn PP; Cruts M; Van Broeckhoven C
    Lancet Neurol; 2012 Jan; 11(1):54-65. PubMed ID: 22154785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72.
    Savica R; Adeli A; Vemuri P; Knopman DS; Dejesus-Hernandez M; Rademakers R; Fields JA; Whitwell J; Jack CR; Lowe V; Petersen RC; Boeve BF
    Arch Neurol; 2012 Sep; 69(9):1164-9. PubMed ID: 22637471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS.
    Ash PE; Bieniek KF; Gendron TF; Caulfield T; Lin WL; Dejesus-Hernandez M; van Blitterswijk MM; Jansen-West K; Paul JW; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
    Neuron; 2013 Feb; 77(4):639-46. PubMed ID: 23415312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients.
    Xi Z; Zhang M; Bruni AC; Maletta RG; Colao R; Fratta P; Polke JM; Sweeney MG; Mudanohwo E; Nacmias B; Sorbi S; Tartaglia MC; Rainero I; Rubino E; Pinessi L; Galimberti D; Surace EI; McGoldrick P; McKeever P; Moreno D; Sato C; Liang Y; Keith J; Zinman L; Robertson J; Rogaeva E
    Acta Neuropathol; 2015 May; 129(5):715-27. PubMed ID: 25716178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier.
    Russ J; Liu EY; Wu K; Neal D; Suh E; Irwin DJ; McMillan CT; Harms MB; Cairns NJ; Wood EM; Xie SX; Elman L; McCluskey L; Grossman M; Van Deerlin VM; Lee EB
    Acta Neuropathol; 2015 Jan; 129(1):39-52. PubMed ID: 25388784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress.
    Zhang YJ; Jansen-West K; Xu YF; Gendron TF; Bieniek KF; Lin WL; Sasaguri H; Caulfield T; Hubbard J; Daughrity L; Chew J; Belzil VV; Prudencio M; Stankowski JN; Castanedes-Casey M; Whitelaw E; Ash PE; DeTure M; Rademakers R; Boylan KB; Dickson DW; Petrucelli L
    Acta Neuropathol; 2014 Oct; 128(4):505-24. PubMed ID: 25173361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter.
    Gijselinck I; Van Mossevelde S; van der Zee J; Sieben A; Engelborghs S; De Bleecker J; Ivanoiu A; Deryck O; Edbauer D; Zhang M; Heeman B; Bäumer V; Van den Broeck M; Mattheijssens M; Peeters K; Rogaeva E; De Jonghe P; Cras P; Martin JJ; de Deyn PP; Cruts M; Van Broeckhoven C
    Mol Psychiatry; 2016 Aug; 21(8):1112-24. PubMed ID: 26481318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c9RAN translation: a potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia.
    Gendron TF; Cosio DM; Petrucelli L
    Expert Opin Ther Targets; 2013 Sep; 17(9):991-5. PubMed ID: 23844663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Japanese amyotrophic lateral sclerosis patients with GGGGCC hexanucleotide repeat expansion in C9ORF72.
    Konno T; Shiga A; Tsujino A; Sugai A; Kato T; Kanai K; Yokoseki A; Eguchi H; Kuwabara S; Nishizawa M; Takahashi H; Onodera O
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):398-401. PubMed ID: 23012445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene.
    Wen X; Westergard T; Pasinelli P; Trotti D
    Neurosci Lett; 2017 Jan; 636():16-26. PubMed ID: 27619540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS.
    Yamakawa M; Ito D; Honda T; Kubo K; Noda M; Nakajima K; Suzuki N
    Hum Mol Genet; 2015 Mar; 24(6):1630-45. PubMed ID: 25398948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.
    Lagier-Tourenne C; Baughn M; Rigo F; Sun S; Liu P; Li HR; Jiang J; Watt AT; Chun S; Katz M; Qiu J; Sun Y; Ling SC; Zhu Q; Polymenidou M; Drenner K; Artates JW; McAlonis-Downes M; Markmiller S; Hutt KR; Pizzo DP; Cady J; Harms MB; Baloh RH; Vandenberg SR; Yeo GW; Fu XD; Bennett CF; Cleveland DW; Ravits J
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4530-9. PubMed ID: 24170860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration.
    Suh E; Lee EB; Neal D; Wood EM; Toledo JB; Rennert L; Irwin DJ; McMillan CT; Krock B; Elman LB; McCluskey LF; Grossman M; Xie SX; Trojanowski JQ; Van Deerlin VM
    Acta Neuropathol; 2015 Sep; 130(3):363-72. PubMed ID: 26022924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.